Format

Send to

Choose Destination
Eur J Immunol. 1995 Jun;25(6):1765-9.

Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer.

Author information

1
Unité INSERM 152, Institut Cochin de Génétique Moléculaire, Paris, France.

Abstract

Mutations in the p53 tumor suppressor gene are the most frequent genetic alterations found in human tumors. There are mainly point mutations that lead to single amino acid substitutions. The mutated proteins have a longer half-life than wild-type p53 and accumulate in the nucleus of tumor cells. Anti-p53 antibodies have been found in sera of patients with several types of cancers including breast cancer. This report describes a T cell immune response in three patients with breast tumors who had mutated p53 gene and accumulated p53 protein. All showed a humoral response to p53 protein and the T cells of these patients recognized the wild-type p53 protein and proliferated in response to it. The data reported here are relevant to the immune processes leading to autoimmunity and have a bearing on anti-p53 vaccine development in tumor immunology.

PMID:
7615005
DOI:
10.1002/eji.1830250642
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center